Engineering Nano‐ and Microparticles as Oral Delivery Vehicles to Promote Intestinal Lymphatic Drug Transport

Miao, Yang‐Bao; Lin, Yu‐Jung; Chen, Kuan‐Hung; Luo, Po-Kai; Chuang, Shun-Hao; Yu, Yu‐Tzu; Tai, Hsien-Meng; Chen, Chiung‐Tong; Lin, Kun‐Ju; Sung, Hsing‐Wen

doi:10.1002/adma.202104139

Cited by 43 publications

(25 citation statements)

References 248 publications

(358 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, cancer cells are regularly detached from the primary tumor site through the LS and escape inside the lymph nodes. 4 Unfortunately, escaped cancer cells within the lymph nodes are considered a primary source of cancer relapse after the completion of treatment. 5 Therefore, lymphatic drug delivery (LDD) is a promising approach in the treatment of cancer and prevents cancer relapse.…”

Section: Introductionmentioning

confidence: 99%

“…The oral route is characterized by simplicity, painlessness, avoiding the need for hospitalization, and training a person. 4 Physiologically, the LS plays a fundamental role in the absorption of large particles and dietary molecules including lipids, lipophilic vitamins, and lipophilic drugs. 6 Herein, LDD could be achieved by assembling drug cargoes to take the same track of chylomicrons in the endoplasmic reticulum of the enterocytes or absorption through M cells.…”

Section: Introductionmentioning

confidence: 99%

“… 6 Herein, LDD could be achieved by assembling drug cargoes to take the same track of chylomicrons in the endoplasmic reticulum of the enterocytes or absorption through M cells. 4 Orally administered drugs are usually absorbed via the portal vein and exposed to hepatic first-pass metabolism that decreases drug bioavailability. 5 In contrast, the oral dosage forms planned for the LDD could evade hepatic first-pass metabolism and enhance drug bioavailability.…”

Section: Introductionmentioning

confidence: 99%

“… 5 In contrast, the oral dosage forms planned for the LDD could evade hepatic first-pass metabolism and enhance drug bioavailability. 4 In this regard, different types of lipid-based drug delivery systems had been utilized for targeting the LS. 5 …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

PEGylated SLN as a Promising Approach for Lymphatic Delivery of Gefitinib to Lung Cancer

Sherif¹,

Harisa²,

Alanazi³

et al. 2022

IJN

View full text Add to dashboard Cite

Purpose The present study aimed to develop gefitinib-loaded solid lipid nanoparticles (GEF-SLN), and GEF-loaded PEGylated SLN (GEF-P-SLN) for targeting metastatic lung cancer through the lymphatic system. Methods The prepared SLNs were characterized in terms of physicochemical properties, entrapment efficiency, and in-vitro release. Furthermore, ex-vivo permeability was investigated using the rabbit intestine. Cytotoxicity and apoptotic effects were studied against A549 cell lines as a model for lung cancer. Results The present results revealed that the particle size and polydispersity index of the prepared formulations range from 114 to 310 nm and 0.066 to 0.350, respectively, with negative zeta-potential (−14 to −27.6). Additionally, SLN and P-SLN showed remarkable entrapment efficiency above 89% and exhibited sustained-release profiles. The permeability study showed that GEF-SLN and GEF-P-SLN enhanced the permeability of GEF by 1.71 and 2.64-fold, respectively, compared with GEF suspension. Cytotoxicity showed that IC 50 of pure GEF was 3.5 μg/mL, which decreased to 1.95 and 1.8 μg/mL for GEF-SLN and GEF-P-SLN, respectively. Finally, the apoptotic study revealed that GEF-P-SLN decreased the number of living cells from 49.47 to 3.43 when compared with pure GEF. Conclusion These results concluded that GEF-P-SLN is a promising approach to improving the therapeutic outcomes of GEF in the treatment of metastatic lung cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

PEGylated SLN as a Promising Approach for Lymphatic Delivery of Gefitinib to Lung Cancer

Sherif¹,

Harisa²,

Alanazi³

et al. 2022

IJN

View full text Add to dashboard Cite

show abstract

“…After oral administration, yeast cells are taken by microfold cells through Peyer’s patch and are transported via the lymphatic route to the systemic circulation for efficient drug delivery [ 191 ]. The advantage of this strategy is that the orally administered particulate vehicles transported through the intestinal lymphatic system can bypass the hepatic first-pass metabolism, ensuring higher concentrations of therapeutic agents in the circulation and target tissues [ 192 ].…”

Section: Pathogen-based Npsmentioning

confidence: 99%

Bioinspired and Biomimetic Nanomedicines for Targeted Cancer Therapy

Jin

2022

Pharmaceutics

View full text Add to dashboard Cite

Undesirable side effects and multidrug resistance are the major obstacles in conventional chemotherapy towards cancers. Nanomedicines provide alternative strategies for tumor-targeted therapy due to their inherent properties, such as nanoscale size and tunable surface features. However, the applications of nanomedicines are hampered in vivo due to intrinsic disadvantages, such as poor abilities to cross biological barriers and unexpected off-target effects. Fortunately, biomimetic nanomedicines are emerging as promising therapeutics to maximize anti-tumor efficacy with minimal adverse effects due to their good biocompatibility and high accumulation abilities. These bioengineered agents incorporate both the physicochemical properties of diverse functional materials and the advantages of biological materials to achieve desired purposes, such as prolonged circulation time, specific targeting of tumor cells, and immune modulation. Among biological materials, mammalian cells (such as red blood cells, macrophages, monocytes, and neutrophils) and pathogens (such as viruses, bacteria, and fungi) are the functional components most often used to confer synthetic nanoparticles with the complex functionalities necessary for effective nano-biointeractions. In this review, we focus on recent advances in the development of bioinspired and biomimetic nanomedicines (such as mammalian cell-based drug delivery systems and pathogen-based nanoparticles) for targeted cancer therapy. We also discuss the biological influences and limitations of synthetic materials on the therapeutic effects and targeted efficacies of various nanomedicines.

show abstract

State of the Art in Nanomedicine

Song,

Hou

2024

Nanomedicine

View full text Add to dashboard Cite

Engineering Nano‐ and Microparticles as Oral Delivery Vehicles to Promote Intestinal Lymphatic Drug Transport

Cited by 43 publications

References 248 publications

PEGylated SLN as a Promising Approach for Lymphatic Delivery of Gefitinib to Lung Cancer

PEGylated SLN as a Promising Approach for Lymphatic Delivery of Gefitinib to Lung Cancer

Bioinspired and Biomimetic Nanomedicines for Targeted Cancer Therapy

State of the Art in Nanomedicine

Contact Info

Product

Resources

About